These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38929126)

  • 21. The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis.
    Zhou W; Yang X; Jin J; Cheng M; Li Y; Bai Y; Xu J
    Int Urol Nephrol; 2024 Jan; 56(1):181-190. PubMed ID: 37195574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitochondria as a Source and a Target for Uremic Toxins.
    Popkov VA; Silachev DN; Zalevsky AO; Zorov DB; Plotnikov EY
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.
    Gryp T; De Paepe K; Vanholder R; Kerckhof FM; Van Biesen W; Van de Wiele T; Verbeke F; Speeckaert M; Joossens M; Couttenye MM; Vaneechoutte M; Glorieux G
    Kidney Int; 2020 Jun; 97(6):1230-1242. PubMed ID: 32317112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins.
    Florens N; Calzada C; Lyasko E; Juillard L; Soulage CO
    Toxins (Basel); 2016 Dec; 8(12):. PubMed ID: 27999257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxico-pharmacological perspective of the Nrf2-Keap1 defense system against oxidative stress in kidney diseases.
    Saito H
    Biochem Pharmacol; 2013 Apr; 85(7):865-72. PubMed ID: 23333765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An oral adsorbent, AST-120, suppresses oxidative stress in uremic rats.
    Nakagawa N; Hasebe N; Sumitomo K; Fujino T; Fukuzawa J; Hirayama T; Kikuchi K
    Am J Nephrol; 2006; 26(5):455-61. PubMed ID: 17057375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How do Uremic Toxins Affect the Endothelium?
    Cunha RSD; Santos AF; Barreto FC; Stinghen AEM
    Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32575762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uremic Toxins and Vascular Dysfunction.
    Six I; Flissi N; Lenglet G; Louvet L; Kamel S; Gallet M; Massy ZA; Liabeuf S
    Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32570781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure.
    Satoh M; Hayashi H; Watanabe M; Ueda K; Yamato H; Yoshioka T; Motojima M
    Nephron Exp Nephrol; 2003; 95(3):e111-8. PubMed ID: 14646363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.
    UK HARP-III Collaborative Group
    Nephrol Dial Transplant; 2017 Dec; 32(12):2043-2051. PubMed ID: 27646835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebral oxidative stress induces spatial working memory dysfunction in uremic mice: neuroprotective effect of tempol.
    Fujisaki K; Tsuruya K; Yamato M; Toyonaga J; Noguchi H; Nakano T; Taniguchi M; Tokumoto M; Hirakata H; Kitazono T
    Nephrol Dial Transplant; 2014 Mar; 29(3):529-38. PubMed ID: 24030834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.
    Morales J; Palmer BF
    Postgrad Med; 2024 Mar; 136(2):111-119. PubMed ID: 38344772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma Protein Carbonyls as Biomarkers of Oxidative Stress in Chronic Kidney Disease, Dialysis, and Transplantation.
    Colombo G; Reggiani F; Angelini C; Finazzi S; Astori E; Garavaglia ML; Landoni L; Portinaro NM; Giustarini D; Rossi R; Santucci A; Milzani A; Badalamenti S; Dalle-Donne I
    Oxid Med Cell Longev; 2020; 2020():2975256. PubMed ID: 33299524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uremic Toxins and Frailty in Patients with Chronic Kidney Disease: A Molecular Insight.
    Chao CT; Lin SH
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statins in Chronic Kidney Disease-Effects on Atherosclerosis and Cellular Senescence.
    Fularski P; Krzemińska J; Lewandowska N; Młynarska E; Saar M; Wronka M; Rysz J; Franczyk B
    Cells; 2023 Jun; 12(13):. PubMed ID: 37443712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 chronic kidney disease.
    Rossi M; Campbell KL; Johnson DW; Stanton T; Vesey DA; Coombes JS; Weston KS; Hawley CM; McWhinney BC; Ungerer JP; Isbel N
    Arch Med Res; 2014 May; 45(4):309-17. PubMed ID: 24751327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Kelly MS; Lewis J; Huntsberry AM; Dea L; Portillo I
    Postgrad Med; 2019 Jan; 131(1):31-42. PubMed ID: 30449220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein-bound uremic toxins (PBUTs) in chronic kidney disease (CKD) patients: Production pathway, challenges and recent advances in renal PBUTs clearance.
    Daneshamouz S; Eduok U; Abdelrasoul A; Shoker A
    NanoImpact; 2021 Jan; 21():100299. PubMed ID: 35559786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sacubitril/valsartan in chronic kidney disease, the nephrologist point of view.
    Quiroga B; de Santos A; Sapiencia D; Saharaui Y; Álvarez-Chiva V
    Nefrologia (Engl Ed); 2019; 39(6):646-652. PubMed ID: 31027894
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.